Updates and Announcements


The following NEW funding opportunity has been released: Understanding the Pathogenesis and Etiology of Type 1 Diabetes using Biosamples and Subjects from Clinical Studies (DP3)

For more information, please visit the original RFA-DK-15-018 announcement at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-018.html


The following NEW funding opportunity has been released: Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (T1D) (R43/R44)

For more information, please visit the original RFA-DK-15-024 announcement at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-024.html


The following NEW funding opportunity has been released: Type 1 Diabetes Pathfinder Award (DP2)

For more information, please visit the original RFA-DK-15-030 announcement at:


IMI2 has launched a call for Diabetic Kidney Disease Biomarkers (DKD-BM) including:

• Generating candidate biomarkers from existing clinical longitudinal databases, including the possibility that the studies generating these databases might be expanded by these efforts;
• Using these clinical biomarkers to assess preclinical model systems, and select the most appropriate for future translational investigations;
• Back-translating clinical database findings to develop improved in vitro and in vivo models of DKD

Incorporating these novel biomarkers into clinical trials in order to enhance the precision of application and chances of success of future novel therapeutics aimed at slowing and/or reversing this disease.

More information and full text of the call can be found at the IMI website: http://www.imi.europa.eu/content/stage-1-16


The following NEW funding opportunity has been released:
Mechanisms Underlying the Contribution of Type 1 Diabetes Risk-Associated Variants (DP3)


JDRF is pleased to announce the 6th Annual symposium on “Frontiers in Beta Cell Biology” in partnership with the Genomic Institute of the Novartis Foundation (GNF). Dates and speakers can be found in the flyer and registration link on the GNF website as shown below.


On Friday, October 10, 2014 JDRF will be hosting a public scientific workshop entitled “Defining the Early Stages of T1D” from 8:00am until 4:45pm, at the Hyatt Regency located in Bethesda, Maryland. At this event, leading scientific experts will present and discuss the current scientific understanding of the natural history of type 1 diabetes prior to the onset of symptomatic disease, inform clinical trial design, encourage the development of therapies for the early stages of type 1 diabetes, and aid regulatory decision-making.

The objectives of the workshop are to:

  • Garner common understanding of current data on T1D risk detection, staging, and progression
  • Discuss the design and optimization of intervention trials in the early stages of T1D
  • Identify tools needed to improve staging and predict progression of T1D
  • Discuss approaches to validate existing tools and develop new tools

If you are interested in attending this workshop please send an email to stagesoft1d@jdrf.org with your full name and email address. The deadline for registration is October 3, 2014. Registration is limited and we may reach capacity before this date. Thank you for your support and we hope to see you there!


Defining the Early Stages of T1D Workshop Presentations


TrialNet invites individuals to apply to be the TrialNet Network Chair. Deadline: August 20, 2014 


The following NEW TrialNet-relevant funding opportunities have been released:

There will be webinars to help applicants: Webinar on Funding Opportunities For Type 1 Diabetes Biomarkers Research: Living Biobank and Archive Ancillary Studies

Purpose: NIDDK staff will help applicants understand the differences between the following currently available funding opportunities related to biomarkers research:


Dates: September 11, 2014 1:00 p.m.; September 16 1:00 p.m.

All times listed above are Eastern Daylight Time (EDT).

Applicants should only need to attend one of the two scheduled webinars. The content will be the same.

Registration: http://www.niddk.nih.gov/news/events-calendar/Pages/funding-opportunities-for-type-1-diabetes-biomarkers-research-living-biobank-archive-ancillary-studies-09-2014.aspx


The XII International Conference on Bioencapsulation will be held in Bratislava, Slovakia, September 17-19, 2014. JDRF is supporting a focus session on Islet Encapsulation/Biomedical applications. Please click here for more details.


NIH Funding Opportunities in Artificial Pancreas

  • Diabetes Impact Award-Closed Loop Technologies: Clinical, Physiological and Behavioral Approaches to Improve Type 1 Diabetes Outcomes (DP3)
  • Diabetes Impact Award-Closed Loop Technologies: Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3) (RFA-DK-14-015)

LOIs due: Oct 24, 2014
Applications due: November 24, 2014


The American Diabetes Association and JDRF will convene national and global research expertise at the Diabetes and the Microbiome Research Symposium from October 27-29, 2014 in Chicago, Illinois, USA. Click here for further details.


The 2014 Diabetic Complications Consortium (DiaComp) Pilot & Feasibility Program

The NIDDK-sponsored Diabetic Complications Consortium (DiaComp) is soliciting applications for its annual Pilot and Feasibility Program

Applications of 5 pages requesting up to $100,000 for one year are due May 16, 2014.

Current areas of interest include, but are not limited to:

  • Interrogation of human samples or resources with genetics, systems biology, histology, etc.
  • Use of human tissue to better define the histo-pathology and -morphometry of organs affected by systemic diabetes.
  • Use human tissue to identify different molecular and anatomic “subtypes” of end-organ disease.
  • Application of stem cells, including induced pluripotent stem (iPS) cells, and regenerative therapies to the repair and reversal of diabetic complications.
  • Assessment of multiple complications in model systems (C.elegans, zebrafish, drosophila, etc).
  • Pilot studies to assess the role of the microbiome or virome in diabetic complications.
  • Testing the role of genes or loci that arise from ongoing human genetics/sequencing efforts.
  • New approaches to identify genetic or epigenetic alterations associated with susceptibility to or protection from diabetic complications.
  • Use of relevant model systems to accelerate gene X environment (GEI) studies.
  • Pilot studies to determine if epigenetic changes in circulating cells (like pbmc’s) reflect meaningful changes in tissues or organs affected by complications.
  • Linking and coordination of existing databases relevant to complications research.
  • Pilot studies demonstrating the feasibility of pre-consenting existing cohorts for tissue collection or linking Electronic Medical Records (EMRs) to patient samples.
  • Innovative new studies to better define and understand diabetic wound healing in humans.
  • Mechanistic and preclinical studies of chelation therapy (e.g. EDTA) in relevant models of complications.
  • Studies defining the role of immune cells and inflammatory pathways in initiating, exacerbating, and/or potentially resolving diabetes-induced tissue damage in complications-prone end organs.
  • Pilot studies to non-invasively image fibrosis in organs affected by diabetes.
  • Pilot projects that will directly contribute to strategies, tools, or resources for the regeneration of functional nephrons

Who is eligible to apply?

Applications are accepted from both National and International institutions/ organizations.

What funds are available for P&F Projects?

Applicants may request up to $100,000 (direct + indirect costs) Total Costs for one year. The number of awards will depend upon the number, quality, duration, and cost of the applications received. Awards will be made as subcontracts from the DiaComp Coordinating and Bioinformatics Unit (CBU) at the Georgia Regents University and not directly by the NIH.

Timetable for P&F Application Submissions.

May 16th Deadline for applications submitted to the DiaComp CBU.

Sept. 1st Estimated Start Date for DiaComp P&F Project funding.

Contact Information

For more detailed information, please go to http://www.diacomp.org/shared/pilotFeasibility.aspx

Address questions regarding the DiaComp P&F Program:

Richard A. McIndoe, Ph.D. (Director)

Coordinating and Bioinformatics Unit

Georgia Regents University

Phone: 706-721-3542

Fax: 706-721-3688

Email: rmcindoe@gru.edu


Biomarkers Mechanism Panels information. Click here for more information.


The IMI – JDRF Diabetes Patient Focus meeting will take place on 20 May at the Hotel Crowne Plaza – Le Palace in Brussels, Belgium. Click here for the meeting outline.


Webinar on Funding Opportunities for Type 1 Diabetes Biomarkers Research: Living Biobank and Archive Ancillary Studies


Lisa M. Spain, Ph. D.

Project Scientist, Type 1 Diabetes TrialNet

Program Director, Autoimmune Endocrine Diseases and TEDDY

Division of Diabetes, Endocrinology, and Metabolism

National Institutes of Diabetes & Digestive & Kidney Diseases

6707 Democracy Blvd

Bethesda, MD 20892-5460 (for FedEX use 20817)

Phone (301) 451-9871

Fax 301 480-3503



New NIH Funding Opportunities

Living Biobank: PAR-14-064

Biosamples from T1D: PAR-14-065


4th Annual GNF-JDRF Diabetes Research Symposium

When: April 18, 2014

Time: 8:30 AM – 5 PM

Where: The Genomic Institute of the Novartis Foundation (GNF), San Diego, CA

Hosted by: Martin Seidel (GNF) and Richard Insel (JDRF)

Title: New Frontiers in Beta Cell Biology

Invited Speakers and Registration Form: see poster here

Registration required; space is limited.


NIH Funding Opportunities in Artificial Pancreas

The NIDDK has launched a new RFA: Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D): Towards an Artificial Pancreas (SBIR) (R43/R44) RFA-DK-13-028

LOI due: February 14, 2014

Application due: March 14, 2014


JDRF Requests for Applications (RFA): Clinical and Preclinical Studies To Prevent or Treat Hypoglycemia Unawareness. More Information


RFA DK-13-027 entitled Biomarkers for Diabetes Complications – Non-Invasive Measures in the Eye (DP3) was posted in the NIH Guide today. The receipt date is April 7, 2014.

The goal of the RFA is to advance research on biomarkers that are critically needed to detect early stages of diabetic complications and to serve as surrogate end-points in drug development, not only for diabetic retinopathy, but also for other diabetes complications.

The RFA uses the DP3 mechanism that allows funding for the entire project period in the first year of the grant award. Funding for the RFA is through the Type 1 Diabetes Special Funding Program. Please contact me if you have questions about the RFA.


NIDDK RFA: Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3): Click here for details


NIDDK RFA: Understanding Barriers and Facilitators to Type 1 Diabetes Management in Adults (DP3): Click here for details


July 23-August 8, 2013 Webinar on NIDDK’s Grant Competition Process: RFAs for TrialNet Clinical Centers and New TrialNet Clinical Network Hub Webinar: Click here for details


NIDDK has launched a new RFA: PAR-13-228: Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01) http://grants1.nih.gov/grants/guide/pa-files/PAR-13-228.html


The announcement of the EFSD-JDRF-Novo European Programme in Type 1 Diabetes Research has now been posted on the EFSD Web site:



4th Annual GNF-JDRF Diabetes Research Symposium

When: April 18, 2013

Time: 8:30 AM – 5 PM

Where: The Genomic Institute of the Novartis Foundation (GNF), San Diego, CA

Hosted by: Martin Seidel (GNF) and Richard Insel (JDRF)

Title: New Frontiers in Beta Cell Biology

Invited Speakers and Registration Form: see poster here

Registration required; space is limited.


JDRF Requests for Applications (RFA): JDRF Clinical Investigator Training Awards in the Treatment of Type 1 Diabetes. More details.


NIDDK has launched a new RFA. “Bioengineering Interdisciplinary Training for Diabetes Research (T32)” More details.


NIDDK has launched a new RFA. “Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas.” More details.


JDRF Requests for Applications (RFA): Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes. More details.


JDRF Request for Applications (RFA): Training Travel Awards. More details.


Notice of Correction Regarding Resubmissions and Budget Instructions for NIDDK PAR-13-013 “Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3)” More information.


Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) . More information


Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3) More information


JDRF Request for Applications (RFA): Studies Relevant to the Prevention of Human Type 1 Diabetes. More information


JDRF Request for Applications (RFA): Fault Detection Algorithms for Risk Mitigation in Artificial Pancreas Systems: More information.


JDRF Request for Applications (RFA): Insulin Sensor Initiative. More information.


JDRF Request for Applications (RFA): JDRF Autoimmunity and Beta Cell Cure and Prevention Translational Centers. More information.


JDRF Request for Applications (RFA): Biologic Factors and Targets for Promoting Beta Cell Regeneration, Health, and Survival: More information


Established T1D Clinical Research Roadmap, Paving a New Path; A White Paper sponsored by JDRF and The Helmsley Charitable Trust. Several factors have caused a shortfall in established type 1 diabetes (T1D) non-insulin clinical research, despite the fact that T1D is one of the more prevalent autoimmune diseases. New, emerging data could challenge the current thinking surrounding the potential for therapeutic interventions in people with established T1D. Based on these findings, a bolder approach to clinical research in people with established T1D is clearly warranted. Near-term clinical development opportunities in established T1D subjects are evident. Download the report.


JDRF Request for Information (RFI): Biomarkers of Pancreatic Beta Cell Stress and Health Non-Competitive Consortium: More information


JDRF Symposium at EASD – Final Agenda


The 20th International Conference on Bioencapsulation will take place on 9/20-24, 2012. There is an Islet Encapsulation Focus Session. Details on the Islet Encapsulation Focus Session can be found here.


JDRF Mourns the Loss of Dr. Alan Permutt

JDRF is saddened by the loss of a long-time advocate, friend, and inspiring researcher, M. Alan Permutt, MD, who passed away at the age of 72 on Sunday, June 10th after a long battle with cancer. More information.


12th International Conference of the Immunology of Diabetes Society (IDS)

JDRF Travel Scholarships

To apply for a JDRF Travel Scholarship, submit your abstract and scholarship application by March 1st. More information. Additionally, please visit the IDS website (http://www.ids2012.ca/) for more information on IDS 2012.


Faculty Opportunity at The Benroya Research Institute

The Benaroya Research Institute, in Seattle WA, is recruiting an Assistant/Associate Professor with an MD, PhD, or MD/PhD degree whose research focuses on biomedical translational research. More information.


Diabetic Complications Consortium (DCC) Pilot & Feasibility Opportunities 2012

The DCC is currently soliciting P&F proposals that advance the mission of the consortium.

Applications are due Thursday, May 17, 2012 for July start dates.

More information.


The 4th International Conference on Stem Cells and Tissue Formation

July 18th – 20th, 2012

For more information, please visit: http://www.stemcellcongress-dresden.org/


3rd Annual GNF-JDRF Diabetes Research Symposium

Wednesday, April 25th, 2012

8:30 AM – 5:00 PM

Registration is required – seating is limited.

For registration, please go to: http://www.gnf.org/collaborations/jdrf/symposium.htm

More information.


FOCIS 2012 – JDRF Travel Awards for Young Investigators

JDRF will be offering travel awards to support the attendance of JDRF-supported young investigators at FOCIS 2012. This year, FOCIS will be held from June 21-24 in Vancouver, BC. Please visit http://www.focisnet.org/FOCIS/ for further details about the meeting.


PI of a JDRF Training or Career Development Award: Postdoctoral Fellowship (PF), Advanced Postdoctoral Fellowship (APF)/Transition Award, Career Development Award (CDA), or Early Career Patient-oriented Diabetes Research Awards (ECPODRA), scientific lab member of a JDRF sponsored lab working directly on a JDRF sponsored project.

To apply:

Submit an abstract to FOCIS by the deadline of January 25, 2012.

Inform JDRF of your abstract submission and indicate the nature of your association with a specified JDRF grant (email to: elklein@jdrf.org)

Conditions of award:

Present your JDRF-sponsored research at the FOCIS 2012 meeting.


The amount of the award is TBD, and may vary depending on your departure location.

Please be aware that the travel award amount may not cover the complete expenses related to the conference, and that supplementation from your JDRF grant or other sources may be necessary.

JDRF is pleased to continue this partnership with FOCIS in the support of young investigators. Should you have any questions, please contact Emily L. Klein at elklein@jdrf.org or Dr. Simi Ahmed at sahmed@jdrf.org.


A Letter to all JDRF Investigators in Regards to the New JDRF Brand and Logo

We would like to share with you some exciting news about JDRF. Over the past year, JDRF has undertaken a process to evaluate the perception of our organization with our various stakeholders. This process has resulted in a number of evolutionary changes regarding how we speak about JDRF and regarding the images we use to represent JDRF. Read more


The following NIDDK funding opportunity has a Detailed Budget Correction (PAR-11-349):



TEDDY releases RFP on Gene Expression

View the PDF for additional information


NIDDK has launched a new RFA. Please see the following for more information:

Bioengineering Interdisciplinary Training and Education for Type I Diabetes Research (T90/R90)

Purpose: to promote the development of an interdisciplinary workforce for conducting bioengineering research to develop innovative technologies for treatment of type 1 diabetes including creating integrated long term glucose regulated insulin delivery systems (artificial pancreas), beta cell or islet encapsulation for beta cell replacement therapy, and/or beta cell and autoimmunity imaging methods. This FOA will support institutional training and education programs in type 1 diabetes research for postdoctoral level researchers with backgrounds in bioengineering and/or computational sciences.

LOI Due Date: February 14, 2012

Application Due Date: March 14, 2012


Additional Research Opportunities to be considered by JDRF Canadian Clinical Trial Network (JDRF CCTN)

JDRF Canadian Clinical Trial Network (JDRF CCTN) is a platform for clinical research in Southern Ontario to test new treatments and technologies for type 1 diabetes. JDRF CCTN is pleased to explore all additional research opportunities that can be implemented using the JDRF CCTN structure. These opportunities may include partnerships with additional institutions, investigators, and industry.

More information and how to apply. Note that this opportunity is for Canadian applicants only.

RFI Due Date: 12/5/2011


TEDDY releases RFP on Viral Metagenomics and Microbiome

View the PDF for additional information


A number of NIDDK RFAs with upcoming deadlines are listed below. Please see the following for more information:

Small Business Innovation Research to Develop New Methods and Technologies able to Identify Individuals at Risk of Developing Type 1 Diabetes [T1D] (R43)


LOI Due Date: November 22, 2011

Application Due Date: December 22, 2011

Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D) Towards an Artificial Pancreas [(SBIR) (R43/R44)]


LOI Due Date: October 26, 2011

Application Due Date: November 23, 2011

Improving Adherence in Pre-teens, Adolescents and Young Adults with Type 1 Diabetes (DP3)


LOI Due Date: February 2, 2012

Application Due Date: March 2, 2012

Function of Type 1 Diabetes Genes (DP3)


LOI Due Date: February 1, 2012

Application Due Date: February 29, 2012


TEDDY releases RFP on Dietary Biomarkers in T1D

View the PDF for additional information


TEDDY releases RFP on Metabolomics in T1D

View the PDF for additional information


Diabetes TrialNet Information for Research Collaborators

See the following link for additional information: http://www.diabetestrialnet.org/researchers/index.htm


Euro-BioImaging Proof-of-Concept Studies: CALL for USERS open now! (Oct. 1st to Nov.15th, 2011)


NIDDK funding opportunities are now active (note that the first two use the new Type 1 Diabetes Statutory Appropriation funding). See the following links for more information: